Steven Cohen’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Steven Cohen’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,998	Closed	-$38.8K	–	2954
2023 Q2	$38.8K	Sell	1,998 -3,228	-62%	-$76.6K	﹤0.01%	1660
2023 Q1	$148K	Buy	+5,226	New	+$155K	﹤0.01%	1557
2019 Q3	–	Sell	-28,534	Closed	-$1.59M	–	1534
2019 Q2	$1.59M	Buy	+28,534	New	+$1.49M	0.01%	692
2017 Q3	–	Sell	-45,750	Closed	-$3.61M	–	1093
2017 Q2	$3.61M	Buy	+45,750	New	+$3.74M	0.02%	555
2016 Q3	–	Sell	-11,344	Closed	-$440K	–	884
2016 Q2	$440K	Sell	11,344 -188,487	-94%	-$7.85M	﹤0.01%	667
2016 Q1	$8.09M	Buy	+199,831	New	+$12.7M	0.06%	331

Other funds holding EGRX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Steven Cohen's EGRX Position: Q3 2023 in Review

Steven Cohen sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 1,998 shares — an estimated $38.8K sold.

Steven Cohen first reported a position in EGRX in Q1 2016 and held it in 6 quarters. The position peaked at $8.09M in Q1 2016. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

Steven Cohen reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Steven Cohen sold 1,998 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $38.8K.
Steven Cohen first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 6 quarters.
Steven Cohen's Eagle Pharmaceuticals, Inc. position peaked at $8.09M in Q1 2016.
107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Point72 Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.